This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Bovie Medical Corporation Announces Fourth Quarter And Year End Financial Results

Bovie Medical Corporation (the “Company”) (NYSE Amex: BVX), a manufacturer and marketer of electrosurgical products, today announced its financial results for the fourth quarter and year ended December 31, 2010.

Revenues for the fourth quarter ended December 31, 2010 were approximately $6.2 million versus an approximate $6.5 million for the comparable period last year. During the fourth quarter of 2010, we recognized a non-recurring impairment loss of approximately $1.3 million; resulting in a net loss of approximately $(1,369,000) or $(0.08) per share as compared to net income of approximately $27,000 or $.00 per diluted share in the same period last year. The aforementioned impairment loss was the result of our annual evaluation of the future outlook of our patent related to our SEER product line, after which we determined that the asset value was fully impaired; we further calculated the impairment loss to be approximately $1.3 million.

Revenues for the year ended December 31 were approximately $24.2 million versus an approximate $26.9 million for the comparable period last year; resulting in an approximate net loss of $(1,535,000) or $(0.09) per share as compared to an approximate net income of $595,000 or $.03 per diluted share in the same period in the prior year. The decrease in revenues for the year was primarily due to a decline in OEM sales of approximately $3.6 million. The decrease in sales was partially offset by increased domestic and international electrosurgical generators and cauteries sales; with international sales spiking to a record exceeding $5 million. Net loss includes non-recurring expenses of approximately $1.3 million relating to asset impairment, a $300,000 loss on the sale of our St. Petersburg, Florida property and $100,000 on the closing of the Canadian facility. In addition, there were increased professional and consulting fees totaling $145,000.

Andrew Makrides, chief executive officer of Bovie Medical, stated, “The Company continues to place great effort and resources into the development of J-Plasma having submitted a 510k application to the FDA for a new handpiece with retractable cutting features used in both laparoscopic and open procedures. Since the outset of the current fiscal year, surgeons in diverse specialties have evaluated J-Plasma and the feedback received is most encouraging. While awaiting 510k clearance, J-Plasma developmental progress has far exceeded our expectations and management is convinced that its market potential will be the prime engine of Bovie’s future growth.”

1 of 4

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
SYM TRADE IT LAST %CHG

Markets

DOW 17,596.35 -350.33 -1.95%
S&P 500 2,057.64 -43.85 -2.09%
NASDAQ 4,958.4680 -122.0370 -2.40%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs